Tag: boneHealth

Articles

• Foods to eat & avoid during aromatase inhibitor treatment
• Impact of endocrine therapy (hormone therapy) on BC prognosis

News

09/28/11

Zoledronic acid might reduce recurrence in postmenopausal women

12/10/10

Adding zoledronic acid to chemotherapy does not improve markers

02/05/10

Vitamin D and calcium intakes influence risk of breast cancer

Foods

• • black tea
  • blackberries
  • carrots
  • cheese
  • cherries
  • chocolate
  • dry beans
  • flaxseed
  • green tea
  • greens
  • herring and sardines
  • honey
  • kale
  • lake trout
  • mackerel
  • olives and olive oil
  • oranges
  • plums
  • pomegranates
  • salmon
  • tofu
  • yogurt

Studies

• Review on effects and mechanisms of plant-derived natural products against breast cancer bone metastasis Cite
  Zhang X, Miao J, Song Y, Zhang J, Miao M. Review on effects and mechanisms of plant-derived natural products against breast cancer bone metastasis. Heliyon. Elsevier BV; 2024;:e37894 10.1016/j.heliyon.2024.e37894
• Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study Cite
  Blomqvist C, Vehmanen L, Kellokumpu-Lehtinen P, Huovinen R, Ruohola J, Penttinen H, et al. Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07252-7
• Mechanism of synergistic inhibitory effect of benzyl isothiocyanate and zoledronic acid combination on breast cancer induction of osteoclast differentiation Cite
  Hahm E, Kim S, Pore SK, Mathan SV, Singh RP, Singh SV. Mechanism of synergistic inhibitory effect of benzyl isothiocyanate and zoledronic acid combination on breast cancer induction of osteoclast differentiation. Molecular Carcinogenesis. Wiley; 2023; 10.1002/mc.23653
• Delayed versus immediate use of zoledronic acid for postmenopausal patients with ER/PR positive early breast cancer who are using adjuvant letrozole. Cite
  Abdel Gelil M. Delayed versus immediate use of zoledronic acid for postmenopausal patients with ER/PR positive early breast cancer who are using adjuvant letrozole.. JCO Global Oncology. American Society of Clinical Oncology (ASCO); 2023; 9:8-8 10.1200/go.2023.9.supplement_1.8
• Assessment of the Impact of Anti-Hormonal Treatment on Bone Health in Patients With Breast Cancer Using Machine-Learning Analysis Cite
  Park H, Park M, Kim K, Kang T. Assessment of the Impact of Anti-Hormonal Treatment on Bone Health in Patients With Breast Cancer Using Machine-Learning Analysis. Journal of Breast Disease. Korean Breast Cancer Society; 2023; 11:1-10 10.14449/jbd.2023.11.1.1
• Honey: A Promising Therapeutic Supplement for the Prevention and Management of Osteoporosis and Breast Cancer Cite
  Martiniakova M, Kovacova V, Mondockova V, Zemanova N, Babikova M, Biro R, et al. Honey: A Promising Therapeutic Supplement for the Prevention and Management of Osteoporosis and Breast Cancer. Antioxidants. MDPI AG; 2023; 12:567 10.3390/antiox12030567
• Prognostic value of alkaline phosphatase and bone-specific alkaline phosphatase in breast cancer: A systematic review and meta-analysis Cite
  Jiang C, Hu F, Xia X, Guo X. Prognostic value of alkaline phosphatase and bone-specific alkaline phosphatase in breast cancer: A systematic review and meta-analysis. The International Journal of Biological Markers. SAGE Publications; 2023;:039361552311546 10.1177/03936155231154662
• The effects of neoadjuvant zoledronic acid in breast cancer patients: A meta-analysis of randomized controlled trials Cite
  Liu M, Qian S, Wu J, Xiao J, Zeng X. The effects of neoadjuvant zoledronic acid in breast cancer patients: A meta-analysis of randomized controlled trials. Asian Journal of Surgery. Elsevier BV; 2023; 10.1016/j.asjsur.2023.01.049
• Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults Cite
  LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, et al. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. New England Journal of Medicine. Massachusetts Medical Society; 2022; 387:299-309 10.1056/nejmoa2202106
• Influence of alcohol sensitivity on bone metastases and skeletal-related events in primary operable breast cancer: A retrospective cohort study Cite
  Tanda N, Tada H, Washio J, Takahashi N, Ishida T, Koseki T. Influence of alcohol sensitivity on bone metastases and skeletal-related events in primary operable breast cancer: A retrospective cohort study. PLOS ONE. Public Library of Science (PLoS); 2022; 17:e0269335 10.1371/journal.pone.0269335
• Molecular and cellular outcomes of quercetin actions on healthy and tumor osteoblasts Cite
  Lezcano V, Morelli S, González-Pardo V. Molecular and cellular outcomes of quercetin actions on healthy and tumor osteoblasts. Biochimie. Elsevier BV; 2022; 199:46-59 10.1016/j.biochi.2022.04.003
• Mediterranean Diet Food Components as Possible Adjuvant Therapies to Counteract Breast and Prostate Cancer Progression to Bone Metastasis Cite
  Maroni P, Bendinelli P, Fulgenzi A, Ferraretto A. Mediterranean Diet Food Components as Possible Adjuvant Therapies to Counteract Breast and Prostate Cancer Progression to Bone Metastasis. Biomolecules. MDPI AG; 2021; 11:1336 10.3390/biom11091336
• Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer Cite
  Wu K, Feng J, Lyu F, Xing F, Sharma S, Liu Y, et al. Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer. Nature Communications. Springer Science and Business Media LLC; 2021; 12 10.1038/s41467-021-25473-y
• Association between Bone Mineral Density and Bone Turnover Markers in Breast Cancer Patients and Bone-Only Metastasis Cite
  Kundaktepe BP, Sozer V, Kundaktepe FO, Durmus S, Papila C, Uzun H, et al. Association between Bone Mineral Density and Bone Turnover Markers in Breast Cancer Patients and Bone-Only Metastasis. Medicina. MDPI AG; 2021; 57:880 10.3390/medicina57090880
• Tualang Honey Supplementation Improves Inflammatory and Bone Markers among Postmenopausal Breast Cancer Patients: A Randomised Controlled Trial Cite
  Zakaria Z, Wan Ab Hamid WZ, Mohamed M. Tualang Honey Supplementation Improves Inflammatory and Bone Markers among Postmenopausal Breast Cancer Patients: A Randomised Controlled Trial. Sains Malaysiana. Penerbit Universiti Kebangsaan Malaysia (UKM Press); 2021; 50:1971-1985 10.17576/jsm-2021-5007-12
• Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment Cite
  Friedl TWP, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, et al. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment. JAMA Oncology. American Medical Association (AMA); 2021; 10.1001/jamaoncol.2021.1854
• The bone microenvironment invigorates metastatic seeds for further dissemination Cite
  Zhang W, Bado IL, Hu J, Wan Y, Wu L, Wang H, et al. The bone microenvironment invigorates metastatic seeds for further dissemination. Cell. Elsevier BV; 2021; 184:2471-2486.e20 10.1016/j.cell.2021.03.011
• From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors Cite
  Vasconcelos de Matos L, Fernandes L, Neves MT, Alves F, Baleiras M, Ferreira A, et al. From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors. Current Oncology. MDPI AG; 2021; 28:1067-1076 10.3390/curroncol28020104
• Molecular insights into the interplay between adiposity, breast cancer and bone metastasis Cite
  Soni S, Torvund M, Mandal CC. Molecular insights into the interplay between adiposity, breast cancer and bone metastasis. Clinical & Experimental Metastasis. Springer Science and Business Media LLC; 2021; 10.1007/s10585-021-10076-0
• Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial Cite
  Sestak I, Blake G, Patel R, Cuzick J, Howell A, Coleman R, et al. Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial. British Journal of Cancer. Springer Science and Business Media LLC; 2021; 10.1038/s41416-020-01228-2
• Perspective: Characterization of Dietary Supplements Containing Calcium and Magnesium and Their Respective Ratio—Is a Rising Ratio a Cause for Concern? Cite
  Costello RB, Rosanoff A, Dai Q, Saldanha LG, Potischman NA. Perspective: Characterization of Dietary Supplements Containing Calcium and Magnesium and Their Respective Ratio—Is a Rising Ratio a Cause for Concern?. Advances in Nutrition. Oxford University Press (OUP); 2020; 10.1093/advances/nmaa160
• Low Levels of Omega-3 Long-Chain Polyunsaturated Fatty Acids Are Associated with Bone Metastasis Formation in Premenopausal Women with Breast Cancer: A Retrospective Study Cite
  Goupille C, Frank PG, Arbion F, Jourdan M, Guimaraes C, Pinault M, et al. Low Levels of Omega-3 Long-Chain Polyunsaturated Fatty Acids Are Associated with Bone Metastasis Formation in Premenopausal Women with Breast Cancer: A Retrospective Study. Nutrients. MDPI AG; 2020; 12:3832 10.3390/nu12123832
• Most women with breast cancer about to initiate aromatase inhibitors already have bone loss Cite
  Gil RHS, Rodríguez ER, Rodríguez LR, Delgado HR, Jurado JC, Pérez MS, et al. Most women with breast cancer about to initiate aromatase inhibitors already have bone loss. Medicina Clínica Práctica. Elsevier BV; 2020; 4:100156 10.1016/j.mcpsp.2020.100156
• Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells Cite
  Sheweita SA, Ammar RG, Sabra SA, Sultan AS. Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells. Journal of Taibah University Medical Sciences. Elsevier BV; 2020; 10.1016/j.jtumed.2020.10.017
• Association Use of Bisphosphonates with Risk of Breast Cancer: A Meta-Analysis Cite
  Peng R, Liang X, Zhang G, Yao Y, Chen Z, Pan X, et al. Association Use of Bisphosphonates with Risk of Breast Cancer: A Meta-Analysis. BioMed Research International. Hindawi Limited; 2020; 2020:1-13 10.1155/2020/5606573
• Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength Cite
  Burt LA, Billington EO, Rose MS, Raymond DA, Hanley DA, Boyd SK. Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength. JAMA. American Medical Association (AMA); 2019; 322:736 10.1001/jama.2019.11889
• Adverse Effects of High‐Dose Vitamin D Supplementation on Volumetric Bone Density Are Greater in Females than Males Cite
  Burt LA, Billington EO, Rose MS, Kremer R, Hanley DA, Boyd SK. Adverse Effects of High‐Dose Vitamin D Supplementation on Volumetric Bone Density Are Greater in Females than Males. Journal of Bone and Mineral Research. Wiley; 2020; 35:2404-2414 10.1002/jbmr.4152
• Five-year follow-up results of aerobic and impact training on bone mineral density in early breast cancer patients Cite
  Vehmanen L, Sievänen H, Kellokumpu-Lehtinen P, Nikander R, Huovinen R, Ruohola J, et al. Five-year follow-up results of aerobic and impact training on bone mineral density in early breast cancer patients. Osteoporosis International. Springer Science and Business Media LLC; 2020; 10.1007/s00198-020-05611-w
• Selenium donors inhibits osteoclastogenesis through inhibiting IL-6 and plays a pivotal role in bone metastasis from breast cancer Cite
  Zhang L, Wu X, Feng Y, Zheng L, Jian J. Selenium donors inhibits osteoclastogenesis through inhibiting IL-6 and plays a pivotal role in bone metastasis from breast cancer. Toxicology Research. Oxford University Press (OUP); 2020; 9:544-551 10.1093/toxres/tfaa053
• Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307 Cite
  Gralow JR, Barlow WE, Paterson AHG, M'iao JL, Lew DL, Stopeck AT, et al. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2019; 112:698-707 10.1093/jnci/djz215
• Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does it Matter? Cite
  Brufsky A, Mathew A. Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does it Matter?. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2019; 112:659-660 10.1093/jnci/djz216
• Survival in older women with early stage breast cancer receiving low‐dose bisphosphonates or denosumab Cite
  Suarez‐Almazor ME, Herrera R, Lei X, Chavez‐MacGregor M, Zhao H, Giordano SH. Survival in older women with early stage breast cancer receiving low‐dose bisphosphonates or denosumab. Cancer. Wiley; 2020; 126:3929-3938 10.1002/cncr.33035
• Physical activity among patients with breast cancer receiving aromatase inhibitors is associated with bone health: a cross-sectional observational study Cite
  Saito T, Ono R, Kono S, Asano M, Fukuta A, Tanaka Y, et al. Physical activity among patients with breast cancer receiving aromatase inhibitors is associated with bone health: a cross-sectional observational study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 182:187-193 10.1007/s10549-020-05668-5
• Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial Cite
  van Hellemond IEG, Smorenburg CH, Peer PGM, Swinkels ACP, Seynaeve CM, van der Sangen MJC, et al. Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:675-685 10.1007/s10549-020-05567-9
• Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients Cite
  Kim M, Kim H, Ahn SH, Tabatabaie V, Choi SW, Sohn G, et al. Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:657-663 10.1007/s10549-020-05566-w
• Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study Cite
  Yao S, Laurent CA, Roh JM, Lo J, Tang L, Hahn T, et al. Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:187-195 10.1007/s10549-019-05518-z
• Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials Cite
  Qian X, Li Z, Ruan G, Tu C, Ding W. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 179:275-285 10.1007/s10549-019-05464-w
• Characteristics of adverse events of endocrine therapies among older patients with breast cancer Cite
  Honma N, Makita M, Saji S, Mikami T, Ogata H, Horii R, et al. Characteristics of adverse events of endocrine therapies among older patients with breast cancer. Supportive Care in Cancer. Society for Mining, Metallurgy and Exploration Inc.; 2019; 27:3813-3822 10.1007/s00520-019-04674-8
• Bisphosphonate use in geriatric breast cancer patients on aromatase inhibitors in a rural population. Cite
  Johnson A, Agbisit C, Robinson K, Delfino K, Desai MR. Bisphosphonate use in geriatric breast cancer patients on aromatase inhibitors in a rural population.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:e12048-e12048 10.1200/jco.2019.37.15_suppl.e12048
• The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women Cite
  Rouach V, Goldshtein I, Buch A, Catane R, Chodick G, Stern N, et al. The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women. Journal of Bone Oncology. Elsevier BV; 2019; 16:100202 10.1016/j.jbo.2018.10.001
• Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation Cite
  Tanaka M, Itoh S, Takeuchi Y. Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation. Osteoporosis and Sarcopenia. Elsevier BV; 2018; 4:102-108 10.1016/j.afos.2018.08.002
• Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors Cite
  Bouvard B, Chatelais J, Soulié P, Hoppé E, Saulnier P, Capitain O, et al. Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors. European Journal of Cancer. Elsevier BV; 2018; 101:87-94 10.1016/j.ejca.2018.06.028
• Olive Oil Consumption and Bone Microarchitecture in Spanish Women Cite
  Roncero-Martín R, Aliaga Vera I, Moreno-Corral L, Moran J, Lavado-Garcia J, Pedrera-Zamorano J, et al. Olive Oil Consumption and Bone Microarchitecture in Spanish Women. Nutrients. MDPI AG; 2018; 10:968 10.3390/nu10080968
• Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial Cite
  Kyvernitakis I, Kann PH, Thomasius F, Hars O, Hadji P. Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial. Bone. Elsevier BV; 2018; 114:109-115 10.1016/j.bone.2018.06.007
• Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy Cite
  Neuner JM, Shi Y, Kong AL, Kamaraju S, Smith EC, Smallwood AJ, et al. Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy. Journal of Cancer Survivorship. Springer Science and Business Media LLC; 2017; 12:268-275 10.1007/s11764-017-0666-4
• Coffee and tea drinking in relation to risk of hip fracture in the Singapore Chinese Health Study Cite
  Dai Z, Jin A, Soh AZ, Ang L, Yuan J, Koh W. Coffee and tea drinking in relation to risk of hip fracture in the Singapore Chinese Health Study. Bone. Elsevier BV; 2018; 112:51-57 10.1016/j.bone.2018.04.010
• Bisphosphonate Use and Risk of Recurrence, Second Primary Breast Cancer, and Breast Cancer Mortality in a Population-Based Cohort of Breast Cancer Patients Cite
  Korde LA, Doody DR, Hsu L, Porter PL, Malone KE. Bisphosphonate Use and Risk of Recurrence, Second Primary Breast Cancer, and Breast Cancer Mortality in a Population-Based Cohort of Breast Cancer Patients. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2017; 27:165-173 10.1158/1055-9965.epi-17-0556
• Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy Cite
  Kwan ML, Yao S, Laurent CA, Roh JM, Quesenberry CP, Kushi LH, et al. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 168:523-530 10.1007/s10549-017-4626-5
• Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro Cite
  Gschwantler-Kaulich D, Weingartshofer S, Grunt TW, Mairhofer M, Tan Y, Gamper J, et al. Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro. PLOS ONE. Public Library of Science (PLoS); 2017; 12:e0185566 10.1371/journal.pone.0185566
• Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis Cite
  Goldvaser H, Barnes TA, Šeruga B, Cescon DW, Ocaña A, Ribnikar D, et al. Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2017; 110:31-39 10.1093/jnci/djx141
• Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies Cite
  Ou Y, Chiu H, Wong Y, Yang C, Yang Y. Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies. Pharmacoepidemiology and Drug Safety. Wiley; 2017; 26:1286-1295 10.1002/pds.4302
• Use of Bisphosphonates and Risk of Breast Cancer in a French Cohort of Postmenopausal Women Cite
  Fournier A, Mesrine S, Gelot A, Fagherazzi G, Baglietto L, Clavel-Chapelon F, et al. Use of Bisphosphonates and Risk of Breast Cancer in a French Cohort of Postmenopausal Women. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:3230-3239 10.1200/jco.2016.71.4337
• Antiosteoporotic activity of a syringic acid diet in ovariectomized mice Cite
  Tanaka T, Kawaguchi N, Zaima N, Moriyama T, Fukuta Y, Shirasaka N. Antiosteoporotic activity of a syringic acid diet in ovariectomized mice. Journal of Natural Medicines. Springer Science and Business Media LLC; 2017; 71:632-641 10.1007/s11418-017-1105-6
• Abstract 5258: Benzyl isothiocyanate prevents breast cancer-induced bone erosionin vivo Cite
  Pore SK, Singh SV. Abstract 5258: Benzyl isothiocyanate prevents breast cancer-induced bone erosionin vivo. Prevention Research. American Association for Cancer Research; 2017; 10.1158/1538-7445.am2017-5258
• Premenopausal women with early breast cancer treated with estradiol suppression have severely deteriorated bone microstructure Cite
  Ramchand SK, Seeman E, Wang X, Ghasem-Zadeh A, Francis PA, Ponnusamy EJ, et al. Premenopausal women with early breast cancer treated with estradiol suppression have severely deteriorated bone microstructure. Bone. Elsevier BV; 2017; 103:131-135 10.1016/j.bone.2017.06.024
• Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG Cite
  Hadji P, Aapro MS, Body J, Gnant M, Brandi ML, Reginster JY, et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. Journal of Bone Oncology. Elsevier BV; 2017; 7:1-12 10.1016/j.jbo.2017.03.001
• Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells Cite
  Ubellacker JM, Haider M, DeCristo MJ, Allocca G, Brown NJ, Silver DP, et al. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells. Breast Cancer Research. Springer Science and Business Media LLC; 2017; 19 10.1186/s13058-017-0815-8
• Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer Cite
  Hong AR, Kim JH, Lee KH, Kim TY, Im SA, Kim TY, et al. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer. Osteoporosis International. Springer Science and Business Media LLC; 2017; 28:1413-1422 10.1007/s00198-016-3899-6
• The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors Cite
  Thomas GA, Cartmel B, Harrigan M, Fiellin M, Capozza S, Zhou Y, et al. The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors. Obesity. Wiley; 2016; 25:346-351 10.1002/oby.21729
• Dietary Inflammatory Index, Bone Mineral Density, and Risk of Fracture in Postmenopausal Women: Results From the Women's Health Initiative Cite
  Orchard T, Yildiz V, Steck SE, Hébert JR, Ma Y, Cauley JA, et al. Dietary Inflammatory Index, Bone Mineral Density, and Risk of Fracture in Postmenopausal Women: Results From the Women's Health Initiative. Journal of Bone and Mineral Research. Wiley; 2017; 32:1136-1146 10.1002/jbmr.3070
• The Effect of Bone-Loading Exercise on Bone Mineral Density in Women Following Treatment for Breast Cancer Cite
  Zerzan S, Smoot B, Lee JQ, Lui A, Allen DD. The Effect of Bone-Loading Exercise on Bone Mineral Density in Women Following Treatment for Breast Cancer. Rehabilitation Oncology. Ovid Technologies (Wolters Kluwer Health); 2016; 34:144-155 10.1097/01.reo.0000000000000039
• Change in bone mineral density during adjuvant chemotherapy for early-stage breast cancer Cite
  Christensen CØ, Cronin-Fenton D, Frøslev T, Hermann AP, Ewertz M. Change in bone mineral density during adjuvant chemotherapy for early-stage breast cancer. Supportive Care in Cancer. Springer Science and Business Media LLC; 2016; 24:4229-4236 10.1007/s00520-016-3250-y
• Abstract 3318: Exploring the utility of natural and synthetic resveratrol derivatives for bone regrowth following loss due to breast cancer therapies Cite
  Robert E, Rhodes LV. Abstract 3318: Exploring the utility of natural and synthetic resveratrol derivatives for bone regrowth following loss due to breast cancer therapies. Tumor Biology. American Association for Cancer Research; 2016; 10.1158/1538-7445.am2016-3318
• Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years Cite
  Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal of Medicine. Massachusetts Medical Society; 2016; 375:209-219 10.1056/nejmoa1604700
• Osteoporosis and pain severity in reproductive age patients with breast cancer Cite
  Tretyakova NY, Chizhikov AV. Osteoporosis and pain severity in reproductive age patients with breast cancer. Kazan medical journal. ECO-Vector LLC; 2016; 97:207-212 10.17750/kmj2016-207
• Periodontal health in breast cancer patients on aromatase inhibitors versus postmenopausal controls: a longitudinal analysis Cite
  Eagle I, Benavides E, Eber R, Kolenic G, Jung Y, Van Poznak C, et al. Periodontal health in breast cancer patients on aromatase inhibitors versus postmenopausal controls: a longitudinal analysis. Journal of Clinical Periodontology. Wiley; 2016; 43:659-667 10.1111/jcpe.12562
• Osteocytic connexin hemichannels suppress breast cancer growth and bone metastasis Cite
  Zhou JZ, Riquelme MA, Gu S, Kar R, Gao X, Sun L, et al. Osteocytic connexin hemichannels suppress breast cancer growth and bone metastasis. Oncogene. Springer Science and Business Media LLC; 2016; 35:5597-5607 10.1038/onc.2016.101
• Can a healthy life prevent us from post-menopausal osteoporosis? Myths and truths Cite
  Herrero S, Pico Y. Can a healthy life prevent us from post-menopausal osteoporosis? Myths and truths. PharmaNutrition. Elsevier BV; 2016; 4:45-53 10.1016/j.phanu.2016.02.003
• Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial Cite
  Prasad C, Greenspan SL, Vujevich KT, Brufsky A, Lembersky BC, van Londen G, et al. Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial. Bone. Elsevier BV; 2016; 90:123-126 10.1016/j.bone.2016.03.010
• Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons Cite
  Markopoulos C, Koukouras D, Venizelos V, Karyda I, Xepapadakis G, Misitzis J, et al. Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons. The Breast. Elsevier BV; 2016; 27:27-34 10.1016/j.breast.2016.02.007
• Phenolic Compounds in Extra Virgin Olive Oil Stimulate Human Osteoblastic Cell Proliferation Cite
  García-Martínez O, De Luna-Bertos E, Ramos-Torrecillas J, Ruiz C, Milia E, Lorenzo ML, et al. Phenolic Compounds in Extra Virgin Olive Oil Stimulate Human Osteoblastic Cell Proliferation. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0150045 10.1371/journal.pone.0150045
• Assessing the prevalence of compromised bone health among overweight and obese African-American breast cancer survivors: a case–control study Cite
  Sheean P, Liang H, Schiffer L, Arroyo C, Troy K, Stolley M. Assessing the prevalence of compromised bone health among overweight and obese African-American breast cancer survivors: a case–control study. Journal of Cancer Survivorship. Springer Science and Business Media LLC; 2015; 10:21-30 10.1007/s11764-015-0448-9
• Greater serum carotenoid concentration associated with higher bone mineral density in Chinese adults Cite
  Zhang Z, Cao W, Liu J, Cao Y, Su Y, Chen Y. Greater serum carotenoid concentration associated with higher bone mineral density in Chinese adults. Osteoporosis International. Springer Science and Business Media LLC; 2016; 27:1593-1601 10.1007/s00198-015-3425-2
• Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance Cite
  Servitja S, Martos T, Rodriguez Sanz M, Garcia-Giralt N, Prieto-Alhambra D, Garrigos L, et al. Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance. Therapeutic Advances in Medical Oncology. SAGE Publications; 2015; 7:291-296 10.1177/1758834015598536
• Fracture Risk and Adjuvant Therapies in Young Breast Cancer Patients: A Population-Based Study Cite
  Chang C, Chen S, Liu C. Fracture Risk and Adjuvant Therapies in Young Breast Cancer Patients: A Population-Based Study. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0130725 10.1371/journal.pone.0130725
• Tea and bone health: Findings from human studies, potential mechanisms, and identification of knowledge gaps Cite
  Nash LA, Ward WE. Tea and bone health: Findings from human studies, potential mechanisms, and identification of knowledge gaps. Critical Reviews in Food Science and Nutrition. Informa UK Limited; 2015; 57:1603-1617 10.1080/10408398.2014.1001019
• Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer Cite
  Koopal C, Janssen-Heijnen M, van de Wouw A, van den Bergh J. Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer. The Breast. Elsevier BV; 2015; 24:153-158 10.1016/j.breast.2014.12.008
• Bisphosphonates May Protect against Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Aromatase Inhibitor Therapy: Results from a Meta-analysis Cite
  Su G, Xiang Y, He G, Jiang C, Li C, Yan Z, et al. Bisphosphonates May Protect against Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Aromatase Inhibitor Therapy: Results from a Meta-analysis. Archives of Medical Research. Elsevier BV; 2014; 45:570-579 10.1016/j.arcmed.2014.10.007
• Pomegranate and its derivatives can improve bone health through decreased inflammation and oxidative stress in an animal model of postmenopausal osteoporosis Cite
  Spilmont M, Léotoing L, Davicco M, Lebecque P, Mercier S, Miot-Noirault E, et al. Pomegranate and its derivatives can improve bone health through decreased inflammation and oxidative stress in an animal model of postmenopausal osteoporosis. European Journal of Nutrition. Springer Science and Business Media LLC; 2013; 53:1155-1164 10.1007/s00394-013-0615-6
• A Survey of Joint and Muscle Aches, Pain, and Stiffness Comparing Women With and Without Breast Cancer Cite
  Fenlon D, Addington-Hall JM, O’Callaghan AC, Clough J, Nicholls P, Simmonds P. A Survey of Joint and Muscle Aches, Pain, and Stiffness Comparing Women With and Without Breast Cancer. Journal of Pain and Symptom Management. Elsevier BV; 2013; 46:523-535 10.1016/j.jpainsymman.2012.10.282
• The citrus flavonone hesperetin prevents letrozole-induced bone loss in a mouse model of breast cancer Cite
  Li F, Chow S, Cheung W, Chan FL, Chen S, Leung LK. The citrus flavonone hesperetin prevents letrozole-induced bone loss in a mouse model of breast cancer. The Journal of Nutritional Biochemistry. Elsevier BV; 2013; 24:1112-1116 10.1016/j.jnutbio.2012.08.010
• Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results Cite
  Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Annals of Oncology. Elsevier BV; 2013; 24:398-405 10.1093/annonc/mds277
• Induced osteoclastogenesis by fluoroquinolones in unstimulated and stimulated human osteoclast precursor cells Cite
  Costa-Rodrigues J, Martins E, Fernandes M. Induced osteoclastogenesis by fluoroquinolones in unstimulated and stimulated human osteoclast precursor cells. Bone. Elsevier BV; 2012; 51:17-27 10.1016/j.bone.2012.03.015
• The Blackberry Fruit: A Review on Its Composition and Chemistry, Metabolism and Bioavailability, and Health Benefits Cite
  Kaume L, Howard LR, Devareddy L. The Blackberry Fruit: A Review on Its Composition and Chemistry, Metabolism and Bioavailability, and Health Benefits. Journal of Agricultural and Food Chemistry. American Chemical Society (ACS); 2011; 60:5716-5727 10.1021/jf203318p
• Yerba Mate (Ilex paraguariensis) consumption is associated with higher bone mineral density in postmenopausal women Cite
  Conforti AS, Gallo ME, Saraví FD. Yerba Mate (Ilex paraguariensis) consumption is associated with higher bone mineral density in postmenopausal women. Bone. Elsevier BV; 2012; 50:9-13 10.1016/j.bone.2011.08.029
• Bisphosphonate Use After Estrogen Receptor-Positive Breast Cancer and Risk of Contralateral Breast Cancer Cite
  Monsees GM, Malone KE, Tang MC, Newcomb PA, Li CI. Bisphosphonate Use After Estrogen Receptor-Positive Breast Cancer and Risk of Contralateral Breast Cancer. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2011; 103:1752-1760 10.1093/jnci/djr399
• Final 5-year results of Z-FAST trial Cite
  Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, et al. Final 5-year results of Z-FAST trial. Cancer. Wiley; 2011; 118:1192-1201 10.1002/cncr.26313
• Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07) Cite
  Zaman K, Thürlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J, et al. Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Annals of Oncology. Elsevier BV; 2012; 23:1474-1481 10.1093/annonc/mdr448
• Breast-Cancer Adjuvant Therapy with Zoledronic Acid Cite
  Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-Cancer Adjuvant Therapy with Zoledronic Acid. New England Journal of Medicine. Massachusetts Medical Society; 2011; 365:1396-1405 10.1056/nejmoa1105195
• Polyphenols, isothiocyanates, and carotenoid derivatives enhance estrogenic activity in bone cells but inhibit it in breast cancer cells Cite
  Veprik A, Khanin M, Linnewiel-Hermoni K, Danilenko M, Levy J, Sharoni Y. Polyphenols, isothiocyanates, and carotenoid derivatives enhance estrogenic activity in bone cells but inhibit it in breast cancer cells. American Journal of Physiology-Endocrinology and Metabolism. American Physiological Society; 2012; 303:E815-E824 10.1152/ajpendo.00142.2011
• Soy Isoflavones in the Prevention of Menopausal Bone Loss and Menopausal Symptoms Cite
  Levis S. Soy Isoflavones in the Prevention of Menopausal Bone Loss and Menopausal Symptoms. Archives of Internal Medicine. American Medical Association (AMA); 2011; 171:1363 10.1001/archinternmed.2011.330
• Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer Cite
  Edwards BJ, Raisch DW, Shankaran V, McKoy JM, Gradishar W, Bunta AD, et al. Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer. Clinical Cancer Research. American Association for Cancer Research (AACR); 2011; 17:560-568 10.1158/1078-0432.ccr-10-1595
• Chocolate consumption and bone density in older women Cite
  Hodgson JM, Devine A, Burke V, Dick IM, Prince RL. Chocolate consumption and bone density in older women. The American Journal of Clinical Nutrition. Oxford University Press (OUP); 2008; 87:175-180 10.1093/ajcn/87.1.175
• Association between Plasma 25-Hydroxyvitamin D and Breast Cancer Risk Cite
  Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, Dworakowski E, et al. Association between Plasma 25-Hydroxyvitamin D and Breast Cancer Risk. Cancer Prevention Research. American Association for Cancer Research (AACR); 2009; 2:598-604 10.1158/1940-6207.capr-08-0138
• Pomegranate extract improves a depressive state and bone properties in menopausal syndrome model ovariectomized mice Cite
  Mori-Okamoto J, Otawara-Hamamoto Y, Yamato H, Yoshimura H. Pomegranate extract improves a depressive state and bone properties in menopausal syndrome model ovariectomized mice. Journal of Ethnopharmacology. Elsevier BV; 2004; 92:93-101 10.1016/j.jep.2004.02.006